Sarepta Therapeutics to Reduce Workforce by Approximately 500 Staff Following Challenges with Duchenne Gene Therapy Development

Sarepta Therapeutics to Reduce Workforce by Approximately 500 Staff Following Challenges with Duchenne Gene Therapy Development

Sarepta Therapeutics to Reduce Workforce by Approximately 500 Staff Following Challenges with Duchenne Gene Therapy Development